Abstract
Background: Breast cancer is the most common cancer among females. The estrogen receptor (ER) is expressed in approximately 70% of breast tumors. Tamoxifen is an ER antagonist that is used as adjuvant therapy in the treatment of ER-positive cancers. Approximately 40% of patients develop tamoxifen resistance during treatment. The metabolic state of cancer cells dictates how responsive they are to chemotherapy, and cancer cells can rewire their metabolism to produce resistant phenotypes. We aim to identify altered metabolites and associated pathways in tamoxifen-resistant (TAMR) breast cancer by using gas chromatography-mass spectrometry (GC/MS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
